GlassScriptPhysician profile
Dagmar R Arnold
NPI 1881649432
$8,873.23
in general payments reported to CMS, 2019-2025
29 companies · $1,272 in 2025
The $1,272 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,853 · 2020: $936 · 2021: $1,618 · 2022: $1,204 · 2023: $959 · 2024: $1,032 · 2025: $1,272.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,088 · Consulting Fee: $175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,087.53 |
| Consulting Fee | $175.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $2,144.25 | 2019-2025 | Mounjaro, Lyumjev, Baqsimi |
| Novo Nordisk INC | $1,405.83 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $801.76 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $791.78 | 2019-2022 | |
| Abbvie INC. | $769.40 | 2019-2025 | Synthroid |
| Amneal Pharmaceuticals LLC | $705.97 | 2021-2025 | Unithroid |
| Sanofi US Services INC. | $350.00 | 2021 | |
| Amgen INC. | $300.00 | 2019-2025 | Prolia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $292.56 | 2019-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $214.74 | 2025 | |
| Corcept Therapeutics | $160.50 | 2019-2025 | Korlym |
| Dexcom, INC. | $146.00 | 2025 | Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor, Dexcom G6 Transmitter |
| Beta Bionics, INC. | $118.89 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Xeris Pharmaceuticals, INC. | $109.96 | 2021-2025 | Gvoke Hypopen, Recorlev |
| Amarin Pharma, INC. | $93.06 | 2020-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $92.60 | 2023-2024 | Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $71.60 | 2019-2021 | |
| Radius Health, INC. | $55.84 | 2019-2020 | |
| Cequr Corporation | $43.23 | 2023 | Cequr Simplicity |
| Ibsa Pharma INC. | $38.82 | 2019-2020 | |
| Embecta Corp. | $26.11 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Exact Sciences Corporation | $24.84 | 2023 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $19.87 | 2020 | |
| Madrigal Pharmaceuticals | $19.22 | 2025 | Rezdiffra |
| Pfizer INC. | $16.87 | 2019 | |
| Medtronic, INC. | $16.81 | 2022 | |
| Alfasigma USA, INC. | $15.74 | 2021 | |
| Novartis Pharmaceuticals Corporation | $15.23 | 2022 | |
| Mannkind Corporation | $11.75 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dagmar Arnold listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.